Boceprevir (Victrelis®) è stato approvato per la commercializzazione in Spagna
Testo in Inglese
Press Release
The Ministry of Health approves public funding for a new drug to treat Hepatitis C that significantly increases the probability of a complete cure
- Decision of the Inter-Ministerial Pricing Commission
- The new drug (active ingredient boceprevir) can achieve a cure of this chronic disease in 66% of patients versus 38% obtained with conventional treatments.
- Boceprevir is a prescription drug for hospital use.
- This new drug can reduce the incidence of serious complications such as cirrhosis, liver transplant and hepatocellular carcinoma by 40 to 60%.
- The Ministry of Health has also approved public funding of a new indication for the medicinal product dabigatran for stroke prevention.
- These measures reflect a health policy that aims to improve the efficiency of the system, generating savings without affecting the inclusion in the pharmaceutical budget of therapeutic innovations that can substantially benefit patients.
11th October 2011. The Inter-Ministerial Pricing Commission, under the authority of the Ministry of Health, has approved the inclusion of a new drug to treat genotype 1 hepatitis C (the most common in Spain and Europe) on the list of drugs receiving state funding. The new drug (Victrelis, with boceprevir as active ingredient) is the first drug with direct antiretroviral action against hepatitis C and has a better efficacy than the conventional treatments peginterferon alpha and ribavirin.
Data from clinical trials with boceprevir show that when this new drug is used together with conventional treatment, it can be successful in 66% of patients versus the 38% success rate of peginterferon alpha and ribavirin alone. Another important advantage is that this new drug also reduces the patients’ treatment time.
It is an important innovation that greatly improves the response to Hepatitis C infection, which will be available to patients who need it, thanks to public funding. In addition to increasing cure rate in these patients, use of this new drug can reduce the incidence of serious complications associated with hepatitis, such as cirrhosis, liver transplant and hepatocellular carcinoma by 40 to 60%.
As regards conditions of use, this is a prescription drug for hospital diagnosis.
Link alla pagina del Ministero della Salute Spagnolo
